Need:

The CEO of a biotech platform technology company needed to assess the strategic fit of its technology in the complement inhibitor space.

Assignment:

MSC was engaged to gather competitive intelligence about inhibitors developed against characterized targets in the immunological cascade to identify development opportunities were the client would have a competitive edge. A shortlist of potential licensees was crafted based on identified drug candidates with technical disadvantages (e.g. short half-life, molecule size, cost of goods, etc.) that the client’s technology would be able to address. The CEO presented the outcome to his board and subsequently used it as a foundation for the company’s collaboration strategy in this space.